Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 77 of 121 for:    stem cell arthritis AND Phase

Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04037345
Recruitment Status : Recruiting
First Posted : July 30, 2019
Last Update Posted : October 16, 2019
Sponsor:
Information provided by (Responsible Party):
Medipost Co Ltd.

Brief Summary:

This clinical trial is performed with patients with knee osteoarthritis who were radiologically diagnosed with Kellgren-Lawrence (K&L) grade 2 or 3. Subjects who voluntarily signed consent form and met inclusion/exclusion criteria, were evaluated eligible and participated in this trial. Investigator selected knee to be evaluated (right or left) and administered investigational product to selected knee on Day 1.

A total of 3 or 6 subjects will be enrolled in low-dose or mid-dose group each, and 6 subjects will be enrolled in high-dose group. The study used a dose escalation scheme (from low-dose to high-dose) to determine the maximum tolerated dose (MTD).


Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Biological: SMUP-IA-01(low-dose) Biological: SMUP-IA-01(mid-dose) Biological: SMUP-IA-01(high-dose) Phase 1

Detailed Description:

All subjects in each dose-group will visit 1 month* (visit 5, 1 month±5 days) after administration of investigational product to evaluate dose limit toxicity (DLT) and determine whether to drop or proceed to next dose level.

Total 5 visit (1week, 1 month, 2 months, 3 months, 6 months) until 6 months after administration of investigational product is planned to assess safety through vial sign, laboratory tests, and exploratory efficacy of IP will be assessed through Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS) and International Knee Documentation Committee (IKDC) subjective knee evaluation.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Open, Single-center, Phase 1 Trial to Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis
Actual Study Start Date : October 7, 2019
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: SMUP-IA-01(low-dose)
A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
Biological: SMUP-IA-01(low-dose)
A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL)
Other Name: Human umbilical cord blood-derived mesenchymal stem cells

Experimental: SMUP-IA-01(mid-dose)
A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
Biological: SMUP-IA-01(mid-dose)
A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL)
Other Name: Human umbilical cord blood-derived mesenchymal stem cells

Experimental: SMUP-IA-01(high-dose)
A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
Biological: SMUP-IA-01(high-dose)
A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)
Other Name: Human umbilical cord blood-derived mesenchymal stem cells




Primary Outcome Measures :
  1. Change of total score in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) compared to baseline at 6 months after treatment [ Time Frame: Baseline, Month 6 ]
    Change of total scorein WOMAC compared to baseline at 6 months after treatment. WOMAC consists of three subscales: pain, stiffness, and physical function, and is performed on baseline (visit 2) and final (Visit 8) visits. Total of 24 questions are evaluated with 5 questions for pain, 2 questions for stiffness, and 17 questions for physical function. Each question is scored between 0 point (no symptom) ~ 4 points (severe symptoms) scale, and the total score is between 0 point (no symptoms) ~ 96 points (higher score representing worse symptoms).


Secondary Outcome Measures :
  1. Change of score in WOMAC three subscales (Pain, stiffness, physical function)compared to baseline at 6 months after treatment [ Time Frame: Baseline, Month 6 ]
    The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).

  2. Change of score in 100 mm VAS (Visual Analogue Scale) compared to baseline [ Time Frame: Baseline, Month 1, Month 2, Month 3, Month 6 ]
    The VAS is a horizontal line, 100 mm in length and anchored by word descriptors at each end (no pain, very severe pain). The patient marks on the line at the point that represents their current state. The VAS score is determined by measuring in millimeters from the left hand end to the point of the mark. The score ranges from "0" or no pain to "100" very severe pain.

  3. Change of score in IKDC(International Knee Documentation Committee)compared to baseline [ Time Frame: Baseline, Month 1, Month 2, Month 3, Month 6 ]
    Change of score in IKDC compared to baseline. IKDC subjective knee evaluation consists of three categories: symptoms, sports activities, and functions. For each category, there are 7 questions for symptoms, 2 questions for sports activities, and 2 questions for functions, a total of 11 questions for evaluation. The scores for each category are summed up and divided into 87, which is the maximum score possible, and then is evaluated by converting it into a scale of 100 points. Higher score indicates better function and less symptoms for the knee.

  4. Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score) compared to baseline at 6 months after treatment [ Time Frame: Baseline, Month 6 ]
    For structural and tissue evaluation of knee, MRI image of detailed knee parts are graded from min. 0 to max. 6. Lower number indicate normal status

  5. Change in K&L(Kellgren-Lawrence) grade compared to the baseline at 3 months and 6 months after treatment [ Time Frame: Baseline, Month 3, Month 6 ]
    The K & L grade is 0 to 4 Grade, which means that the higher the grade, the greater the joint damage and the stenosis of the joint.

  6. Change in joint space width compared to the baseline at 3 months and 6 months after treatment [ Time Frame: Baseline, Month 3, Month 6 ]
    Evaluation of disease progression in target knee as ascertained by change from baseline in joint space width (JSW) determined using radiography

  7. Change in mechanical axis, anatomical axis compared to the baseline at 3 months and 6 months after treatment [ Time Frame: Baseline, Month 3, Month 6 ]
    The degree of deformation of the lower half of the body is measured by measuring the angles of the mechanical axis and the anatomical axis with respect to the vertical axis. Mechanical axis: A line connecting the femoral head center point and the ankle joint center point. Anatomical axis: The middaphyseal line of the femur and tibia.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female over 19 years of age
  2. Subject with knee osteoarthritis (OA) and were diagnosed K&L grade 2 or 3 in radioactive examination at time of screening
  3. Subject with more than 40mm joint pain on the 100-mm VAS, at the time of screening
  4. Subject who were diagnosed as knee osteoarthritis by American College of Rheumatology (ACR) guideline criteria, at the time of screening
  5. Subject with Body mass index (BMI) ≤35 kg/m2 at the time of screening
  6. Subject with ligament instability ≤Grade II (grade o: no ligament instability, grade I: 0 ~ 5㎜, grade Ⅱ: 5 ~ 10 ㎜, grade Ⅲ: > 10 ㎜) at the time of screening
  7. Subject who agree to maintain contraception during study period
  8. Subject who voluntarily agreed to participate in the study, and signed informed consent

Exclusion Criteria:

  1. Subject with myocardial infarction, congestive heart failure, and other severe heart disease or hypertension (or medical history of hypertension) that are not controlled below 140/90mmHg even with treatment with more than three(3) antihypertensive drugs
  2. Subject with serious medical conditions other than cardiovascular disease
  3. Subject with, or with a medical history of auto-immune diseases
  4. Subject with an infection that requires parenteral antibiotic administration.
  5. Subject with a medical history of mental disorder or epilepsy
  6. Subject with chronic inflammatory joint diseases such as rheumatoid arthritis (e.g., osteoarthritis with infectious joint disease, gouty arthritis, and osteoarthritis)
  7. Subject who had surgery or radiation therapy on knee joint area, or have not recovered from side effects of knee joint surgery within 12 weeks before screening
  8. Subject who are pregnant or lactating
  9. Subject abuse alcohol 10 times a week or smoke 25 cigarettes a day
  10. Subject who were diagnosed with cancer within 5 years before screening
  11. Subject who particiapted in another clinical trial within 4 weeks before screening of this clinical trial
  12. Subject who were administered with immunosuppressnats such as cyclosporin A or azathioprine within 6 weeks before screening
  13. Subject who had intra-articular administration such as sodium hyaluronate injections within 6 month before screening
  14. Subject who are suffering from skin disease or considered inappropriate for injection in the injection site
  15. Subject who has history of allergic response to hyaluronate injections or DMSO (cryopreservative) or Gentamicin (antibiotics)
  16. Subject who are consiered inappropriate for MRI assessment with Tesla higher than 3.0
  17. Subject with medical history of cell therapy product administration or are scheduled to administer other cell therapy product
  18. Subject who principal investigator (PI) considers inappropriate to participate in the study due to any reasons other than those listed above

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04037345


Contacts
Layout table for location contacts
Contact: Eunyoung Lee 82234656748 ley0113@medi-post.co.kr

Locations
Layout table for location information
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Jongno-gu, Korea, Republic of, 03080
Contact: Myungchul Lee, MD, PhD         
Sponsors and Collaborators
Medipost Co Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Myungchul Lee, MD, PhD Seoul National University Hospital

Layout table for additonal information
Responsible Party: Medipost Co Ltd.
ClinicalTrials.gov Identifier: NCT04037345     History of Changes
Other Study ID Numbers: MP-SMUP-IA-01-P01
First Posted: July 30, 2019    Key Record Dates
Last Update Posted: October 16, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medipost Co Ltd.:
human umbilical cord blood derived mesenchymal stem cells
Knee Osteoarthritis
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases